| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Medroxyprogesterone (MPA) is a synthetic steroid which is used in the treatment of renal carcinoma. It is a synthetic progestational hormone used in veterinary practice as an estrus regulator.
| ln Vitro |
In T47D cells, medroxyprogesterone (10 nM, 48 h) stimulates the production of Cyclin D1 via the PI3K/Akt signaling pathway, hence promoting cell proliferation [1]. By raising the expression of signaling molecules in HUVECs, medroxyprogesterone (100 nM, 24 h) increases the number of monocyte markers on HUVECs, which may be the cause of atherosclerosis [2].
|
|---|---|
| ln Vivo |
Although it can enhance thrombosis, medroxyprogesterone (27.7 μg/day, subcutaneous injection) inhibits arterial vascular thrombosis [3].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: T47D Tested Concentrations: 10 nM Incubation Duration: 24 h, 48 h, 72h Experimental Results: Increased cell number at 48 hrs (hours). Western Blot Analysis [1] Cell Types: T47D Tested Concentrations: 10 nM Incubation Duration: 4 h Experimental Results: Induced Cyclin D1 protein expression. RT-PCR[2] Cell Types: HUVEC Tested Concentrations: 100 nM Incubation Duration: 24 hrs (hours) Experimental Results: Increased mRNA and protein expression of adhesion molecules. |
| Animal Protocol |
Animal/Disease Models: ApoE-/- mouse model [3]
Doses: 27.7 μg/day Route of Administration: sc Experimental Results: diminished atherosclerotic plaque and increased thrombosis. |
| References |
[1]. Saitoh M, et al. Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology. 2005 Nov;146(11):4917-25.
[2]. Ito F, et al. Medroxyprogesterone acetate enhances monocyte-endothelial interaction under flow conditions by stimulating the expression of cell adhesion molecules. J Clin Endocrinol Metab. 2014 Jun;99(6):2188-97. [3]. Freudenberger T, et al. Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice. Br J Pharmacol. 2009 Dec;158(8):1951-60. |
| Molecular Formula |
C22H32O3
|
|---|---|
| Molecular Weight |
344.5
|
| Exact Mass |
344.2351
|
| CAS # |
520-85-4
|
| Related CAS # |
Medroxyprogesterone (Standard);520-85-4;Medroxyprogesterone-d3;162462-69-3;Medroxyprogesterone-d7
|
| SMILES |
CC([C@@]1(O)CC[C@@]2([H])[C@]3([H])C[C@H](C)C4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O
|
| InChi Key |
FRQMUZJSZHZSGN-HBNHAYAOSA-N
|
| InChi Code |
InChI=1S/C22H32O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h12-13,16-18,25H,5-11H2,1-4H3/t13-,16+,17-,18-,20+,21-,22-/m0/s1
|
| Chemical Name |
Pregn-4-ene-3,20-dione, 17-hydroxy-6-alpha-methyl-
|
| Synonyms |
Medroxyprogesterone; NSC 27408; NSC-27408; NSC27408;
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~145.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9028 mL | 14.5138 mL | 29.0276 mL | |
| 5 mM | 0.5806 mL | 2.9028 mL | 5.8055 mL | |
| 10 mM | 0.2903 mL | 1.4514 mL | 2.9028 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
